Figure 3.

Identification of druggable molecular targets in PDX-mLung. PDX-mLung mice were randomized (n = 5 per group) to receive the fibroblast growth factor receptor inhibitor lenvatinib alone (10 mg/kg given orally five days per week), the cell cycle inhibitor palbociclib alone (100 mg/kg given orally five days per week), and a combination of lenvatinib (5 mg/kg given orally five days per week) and palbociclib (50 mg/kg given orally five days per week). Control animals were left untreated. (A) Whole-body ¹⁸F-FDG PET imaging was used to monitor tumor growth by calculating mean standardized uptake values (SUVmean), (B) tumor volume, (C) gross tumors, and (D) tumor weight. *** p < 0.0001.